# A Real-world Analysis of Concomitant Medication Use Among Metastatic Breast Cancer Patients Treated With CDK4/6 Inhibitors

> **NCT05141240** · — · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 4650 (actual)

## Conditions studied

- Metastatic Breast Cancer

## Interventions

- **DRUG:** Ribiciclib
- **DRUG:** Palbociclib
- **DRUG:** Abemaciclib

## Key facts

- **NCT ID:** NCT05141240
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2020-04-15
- **Primary completion:** 2020-06-15
- **Final completion:** 2020-06-15
- **Target enrollment:** 4650 (ACTUAL)
- **Last updated:** 2021-12-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05141240

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05141240, "A Real-world Analysis of Concomitant Medication Use Among Metastatic Breast Cancer Patients Treated With CDK4/6 Inhibitors". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT05141240. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*